Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The thread of life -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (294)	3/23/2002 2:28:58 PM
From: Mike McFarland	Read Replies (2) \| Respond to of 1336

Misc notes The Kadowaki lab mentioned in the Yahoo post is also mentioned here: arabmedmag.com Kadowaki and his colleagues in Japan, who have made major contributions in the study of PPAR-gamma, found adiponectin to be increased in PPAR-gamma heterozygous- deficient mice who were protected from high-fat-diet induced insulin resistance/diabetes. Oh, here is something to print off: sdu.dk fwiw Googling for PPAR peroxisome proliferator-activated receptor snags this from the google cache Novo Nordisk DRF-2725 (NN622) AstraZeneca AZ 242 SmithKline Beecham rosiglitazone Takeda Chemicals pioglitazone It is good to see the Scherer lab is still working with this. Although to me, "acrp30 is a biomarker..." doesn't sound encouraging. Off topic, stumbled on this alzlab.cwru.edu So I guess the interesting search to perform is this one: google.com Thanks for enduring all this flailing around! Bottom line for now, hold the shares for fun. Get outside and go for a run. Fat cells is bad.